MWN109 / Minwei Biotech - LARVOL DELTA

MWN109—A Novel Fatty Acid–Modified GLP-1/GIP/GCG Triagonist for Dual-Format Weight Management Demonstrates Superior Efficacy in Nonhuman Primates (ADA 2025) - "This study evaluates its weight loss efficacy, pharmacokinetics, and safety in NHP. In diet-induced obesity (DIO) monkey studies, SC MWN109 was compared with tirzepatide and retatrutide. MWN109 exhibits greater weight loss efficacy, favorable pharmacokinetics, and a promising safety profile, supporting its potential as a next-generation obesity treatment. The SC formulation has received IND clearance from both the NMPA and FDA and is currently in Phase 1 trials."

Clinical • Late-breaking abstract • Metabolic Disorders • Obesity • GCG

A phase 1 study to evaluate MWN109 injection in healthy subjects (ANZCTR) - P1 | N=72 | Recruiting | Sponsor: Shanghai Minwei Biotechnology Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2025

Enrollment open • Trial initiation date • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study to Evaluate MWN109 Tablets in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=56 | Not yet recruiting | Sponsor: Shanghai Minwei Biotechnology Co., Ltd

New P1 trial • Genetic Disorders • Obesity

A Study to Evaluate MWN109 Injection in Healthy Subjects (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Shanghai Minwei Biotechnology Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Obesity

A Study to Evaluate MWN109 Injection in Healthy Subjects (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Shanghai Minwei Biotechnology Co., Ltd

New P1 trial • Obesity

A phase 1 study to evaluate MWN109 injection in healthy subjects (ANZCTR) - P1 | N=72 | Not yet recruiting | Sponsor: Shanghai Minwei Biotechnology Co., Ltd.

New P1 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus